Executive Roundtable


The African Union Development Agency (AUDA-NEPAD), the African Union Commission (AUC), and key stakeholders including the Consortium of Partners (in support of the PMPA) are convening the Africa Pharma Conference in Nairobi (2020) to focus on issues and policies that will facilitate sustainable development of regional hubs in best practices. Ideas and initiatives around regional hubs will be explored and this will establish the foundation required for increased access to financial investments, technology and cross-continental capacity development for the pharmaceutical sector and allied ecosystem.

The ‘invite only’ Executive Roundtable at APC 2020 comprises of three (3) 2-hour sessions that bring together principal stakeholders within the Africa Pharma ecosystem to deliberate on critical topics affecting the pharma value chain. The Executive Roundtable will hold on Tuesday June 9, 2020.The boardroom style sessions will feature 15-20 senior stakeholders such as:

  • Ministers of Health, Finance, Trade selected from each region across Africa
  • Senior Executives from Big Pharma such as Novartis, Roche, Takeda, Johnson & Johnson etc 
  • Senior Executives from local manufacturers 
  • Investors investing in Africa Pharma industry
  • Leading Academics and R&D partners
  • Key Opinion Leaders
  • Executives from Health/Pharma Technology providers and the 
  • Media

    For more information on session content, please see the Executive Roundtable brief attached.

Executive Roundtable Speakers

The following speakers have confirmed their participation at the Executive Roundtable

Patrice Matchaba, M.D.

Group Head of Global Health & Corporate Responsibility for Novartis

Patrice Matchaba, M.D., has been Group Head of Global Health & Corporate Responsibility for Novartis since 2017.

From 2014 to 2017, Dr. Matchaba was Global Head of the Cardio-Metabolic development unit at Novartis, where he led the global clinical development of the cardio-metabolic portfolio. He joined Novartis South Africa in 2000 as the Country Pharma Organization Chief Scientific Officer. Since moving to Novartis Pharmaceuticals Corporation in the United States in 2002, he has held several roles of increasing responsibility, such as Therapeutic Area Head for Immunology and Infectious Diseases; Global Head of Drug Safety and Epidemiology; and Global Head of the Integrated Development Functions and Regions, which include Global Clinical Operations, Global Clinical Submissions, Integrated Information Sciences, Development Informatics, Development Diversity and Inclusion, and all Medical Country Pharma Organization regions.

Dr. Matchaba completed his medical training at the University of Zimbabwe, and is a fellow of the College of Obstetrics and Gynecology South Africa. In addition, he is a graduate of Harvard Business School’s Program for Management Development.

Frank Loeffler

Country Manager /Head for Roche East Africa

Frank Loeffler joined Roche in 2001 and worked in both audit and commercial roles after which he worked in pricing and key account management. In 2007, he was appointed head of commercial management for the German Roche affiliate and was responsible for negotiating commercial agreements with hospitals, pharmacies and wholesalers. From 2011 to 2014 he worked in the internal audit department at Roche Headquarters, leading and conducting audits mainly in Asia Pacific and Europe. Frank later worked as regional compliance officer for Eastern Europe, Middle East and Africa (EEMEA) and in 2016 was appointed the Country Manager across East Africa. 

Dr. Suzanne Weissbacher
Global Head of Access to Medicines, Takeda

As the Global Head of Access to Medicines at Takeda, Suzanne Weissbacher is passionate about mobilizing collective action to build and strengthen healthcare systems around the world and at every stage of the patient journey.  With over 15 years of experience working across the public, private and non-governmental sectors, and with a background as a medical doctor, she knows that increasing access to innovative medicines for complex and rare diseases is challenging. It must be approached sustainably and in a targeted way, owned partners on the ground to strengthen healthcare systems at every stage of the patient journey. She was the Head of Healthcare Industries at the World Economic Forum before joining Takeda. She is currently the Global Head of Access to Medicines at Takeda